Latest news with #BloomBurton&Co
National Post
30-04-2025
- Business
- National Post
Covalon to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025
Article content MISSISSAUGA, Ontario — Covalon Technologies Ltd. (the 'Company' or 'Covalon') (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 6, 2025 at 2:30 pm ET in Room 104 B at the Metro Toronto Convention Centre in Toronto. Brent Ashton, CEO of Covalon, will be hosting the presentation and answering questions at the conclusion. Article content Article content During his presentation, Mr. Ashton will share insights into the company's unwavering mission to prevent complications and save lives in healthcare through innovative, patient-centered technologies. He will also discuss Covalon's strong financial position and highlight the company's key growth drivers. Article content 'We are excited to be part of the Bloom Burton 2025 Healthcare Conference, one of the most respected events in the healthcare investment community,' said Ashton. 'Covalon's focus on delivering compassionate care solutions that reduce risks and improve patient outcomes has never been more important. Our strong balance sheet, combined with accelerating growth opportunities, positions us well to drive long-term value for patients, providers, and shareholders.' Article content The Bloom Burton Healthcare Investor Conference brings together healthcare companies and investors to connect and collaborate, offering a premier platform for sharing the latest industry developments and investment opportunities. Article content If you would like to book 1×1 investor meetings with Covalon, and to attend the Bloom Burton & Co. Healthcare Investor Conference, please make sure you are registered here: REGISTER Article content Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Article content The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. Article content About Bloom Burton & Co. Article content Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF). Article content Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Article content This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. Article content Article content Article content Article content Contacts Article content Article content
National Post
29-04-2025
- Business
- National Post
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6. Article content Article content Satellos Co-founder and CEO Frank Gleeson will provide a presentation on May 5 and along with members of the management team, will participate in one-on-one meetings during the conference. Article content 2025 Bloom Burton & Co. Healthcare Investor Conference Format: Presentation and webcast Presenter: Frank Gleeson, President and CEO Date: Monday, May 5 Time: 11:30 a.m. ET Location: Metro Toronto Convention Centre Article content The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation. Article content About Satellos Bioscience Inc. Article content Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity. Satellos has generated a body of preclinical evidence with SAT-3247 to support its discovery that correcting muscle stem cell polarity has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has degenerated or been damaged. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Additionally, Satellos is leveraging its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit Article content Article content Article content Article content Article content Article content
Ottawa Citizen
28-04-2025
- Business
- Ottawa Citizen
enGene to Participate in Upcoming Investor Conferences
Article content Article content Article content BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN or 'enGene' or the 'Company'), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Article content Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Article content Conference: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025 Time: 11:30 a.m. ET Format: Fireside Chat Article content Article content A live webcast of these presentations can be accessed under the 'Investors' section of the enGene website at and will be archived there for 90 days. Article content enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. Article content Article content Article content Article content Contacts Article content Article content
Business Wire
28-04-2025
- Business
- Business Wire
NEUPATH HEALTH TO PRESENT AT THE 2025 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that Joseph Walewicz, CEO, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference to be held May 5 and 6, 2025 at the Metro Toronto Convention Centre. Webcast and replay information for this event will also be available on the Investor Information section of NeuPath's website at: A replay of the webcast will remain available for 90 days following the presentation. About the Conference The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings. For more information, please visit: About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit Forward-Looking Statements This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's Annual Information Form dated March 26, 2025 filed on SEDAR+ under the Company's profile at Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Yahoo
29-01-2025
- Business
- Yahoo
Bloom Burton & Co. Announces the 2025 Bloom Burton Award
Now Accepting Nomination Submissions for the Prestigious Annual Award Toronto, Ontario--(Newsfile Corp. - January 29, 2025) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce the launch of the 2025 Bloom Burton Award and to open nomination submissions from the public at large on or before March 31, 2025. The finalists for the 2025 Bloom Burton Award will be announced at the 2025 Bloom Burton & Co. Healthcare Investor Conference, taking place at the Metro Toronto Convention Centre from May 5-6, 2025. Bloom Burton & Co. Announces the 2025 Bloom Burton AwardTo view an enhanced version of this graphic, please visit: Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada's innovative healthcare industry in the previous year. Nominees will be accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health services or healthcare IT sectors, and equal consideration will be given to contributions across any stage of development – from discovery to commercial end-markets. The winner will be selected by our distinguished panel of judges, comprised of respected international leaders in healthcare investment, entrepreneurship, and journalism: Michael Altman, Managing Director, Perceptive Advisors Christopher Arendt, Chief Scientific Officer, Head of Research, Takeda Karen Bernstein, Co-Founder and Chairman, BioCentury Joan Eliasek, President, McKesson Canada Carl Gordon, Managing Partner, OrbiMed Dennis Purcell, Founder and Senior Advisor, Aisling Capital Melinda Richter, Global Head, Johnson & Johnson Innovation - JLABS Camille Samuels, Director, Venrock Boards Brian Bloom, Chairman & Chief Executive Officer of Bloom Burton commented, "We are honoured to celebrate Canada's top healthcare leaders and welcome the public to submit award nominations for those who achieved monumental success in Canadian healthcare in the past year. We look forward to shining a well-deserved spotlight on the advancements, made by exceptional individuals, that drive our industry forward." The finalists, along with their family and friends, will be invited to attend the Bloom Burton Award Gala on September 25, 2025 at The Ritz-Carlton, Toronto. Each finalist will receive a $25,000 cash prize, and a single winner will receive the 2025 Bloom Burton Award. To submit a nomination, please send a one-page letter by March 31, 2025 to:Karen LiManager, Marketing and Communicationskli@ For table sponsorship and other inquiries:Brian BloomChairman & CEObbloom@ About Bloom Burton & Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF). To view the source version of this press release, please visit Sign in to access your portfolio
